Please assess the completion status of the following clinical trial:

Trial Title: Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proved diagnosis of locally advanced recurrent or metastatic non-squamous NSCLC that is not suitable for local curative treatment.~* Alk-positive NSCLC as determined by a test that is approved or validated for use as a companion diagnostic test.~* No prior systemic therapy for metastatic disease.~* Adjuvant chemotherapy more than 12 months prior to study enrollment.~* Measurable disease as per RECIST 1.1~* ECOG PS 0 or 1.~Exclusion Criteria:~* Prior exposure to ALK receptor tyrosine kinase inhibitor, anti-PD1, anti-PDL1 or any drug targeting T-cell checkpoint pathways.~* known diagnosis of immunodeficiency or is receiving systemic steroid therapy or other form of immunosuppressive therapy within 7 days of clinical trial treatment.~* Active autoimmune disease that has required systemic treatment in the past 3 months.~* History of extensive disseminated interstitial fibrosis or any grade of interstitial lung disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose finding and dose expansion phases (Type: EXPERIMENTAL): Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).